Overview

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants

Status:
Recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV in Healthy Participants
Phase:
Phase 1
Details
Lead Sponsor:
Oneness Biotech Co., Ltd.